Soleno Therapeutics (SLNO) Sparks Confidence Amid Topline Outperformance

On January 20, the terms people connected Soleno Therapeutics (NASDAQ:SLNO) was accrued from $110 to $120 by Ram Selvaraju from H.C. Wainwright. He besides reaffirmed his Buy standing connected the stock, which, arsenic per his forecasts, offers an upside imaginable of astir 211%. The expert based his standing connected the company’s awesome income figures, which proceed to bushed estimates.

Likoper/Shutterstock.com

On January 20, Wells Fargo expert Derek Archila maintained an Overweight standing connected Soleno Therapeutics (NASDAQ:SLNO). He besides raised the terms people from $106 to $114, starring to a revised upside imaginable of 195%.

Archila highlighted fourth-quarter net for Vykat extended-release that surpassed expectations. Although caller PSFs fell short, management’s caller remarks confirmed a people of astir 250 caller starts per quarter, excluding the effects of immoderate seasonal factors. Given the company’s beardown currency travel profile, the expert views shares arsenic presently undervalued.

Soleno Therapeutics (NASDAQ:SLNO) is simply a clinical-stage biopharmaceutical institution processing caller therapies for uncommon diseases specified arsenic Prader-Willi Syndrome. Its starring merchandise is Diazoxide Choline Extended-Release tablets, VYKAT XR. The institution began commercialization of VYKAT XR successful April 2025, pursuing FDA approval.

While we admit the imaginable of SLNO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.